Stoke Therapeutics Stock Price, News & Analysis

Stoke Therapeutics (NASDAQ:STOK), a biotechnology company focused on RNA medicine, announced its participation in the upcoming Canaccord Genuity 45th Annual Growth Conference. Interim CEO Ian F. Smith will deliver a presentation on Wednesday, August 13, 2025, at 11:30 a.m. ET.

The company, which is developing zorevunersen as a potential first-in-class treatment for Dravet syndrome, will make the presentation available via live webcast on their investor relations website, with an archived replay accessible afterward.

Stoke Therapeutics (Nasdaq: STOK), a biotechnology company focused on RNA medicine, has announced inducement grants to three new employees, including newly-appointed Chief People Officer Sara Den Besten. The company granted Ms. Den Besten options to purchase 260,000 shares of common stock at $11.75 per share, while two other employees received options to purchase an aggregate of 130,000 shares.

All options have a 10-year term and will vest over a 4-year period, with 25% vesting after one year and the remainder vesting monthly over the following 36 months. The grants were made under the company's 2023 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4).

Stoke Therapeutics (NASDAQ: STOK), a biotechnology company focused on RNA medicine and protein expression restoration, has granted inducement stock options to two new employees. The grants, effective June 16, 2025, total 37,200 shares with an exercise price of $11.70 per share, matching the company's closing price on that date. The options will vest over 4 years, with 25% vesting after one year and the remainder vesting monthly over 36 months. These 10-year options were granted under the 2023 Inducement Plan as material inducement for employment. Stoke's lead product, zorevunersen, is being developed as a potential first-in-class treatment for Dravet syndrome.

Stoke Therapeutics (NASDAQ: STOK), a biotechnology company focused on RNA medicine to restore protein expression, announced that Interim CEO Ian F. Smith will present at the Jefferies Global Healthcare Conference on June 4, 2025, at 1:25 p.m. ET. The company's lead investigational medicine, zorevunersen, is being developed as a potential first-in-class disease-modifying treatment for Dravet syndrome. A live webcast and replay of the presentation will be accessible through Stoke's investor relations website.

Stoke Therapeutics (NASDAQ: STOK) reported strong Q1 2025 financial results and significant progress in developing zorevunersen for Dravet syndrome. The company achieved regulatory alignment for its Phase 3 EMPEROR study, expected to start in Q2 2025. A notable collaboration with Biogen was established, bringing in $165 million upfront with potential milestone payments of up to $385 million. Stoke maintains exclusive rights in North America while Biogen gets rest-of-world commercialization rights. Q1 2025 financials showed net income of $112.9 million ($1.90 per diluted share), compared to a loss in 2024. The company's strong cash position of $380.3 million is expected to fund operations through mid-2028, supporting Phase 3 data readout and launch preparations.

Stoke Therapeutics (Nasdaq: STOK), a biotechnology company focused on RNA medicine to restore protein expression, has announced its participation in the 24th Annual Needham Virtual Healthcare Conference.

The company's Interim Chief Executive Officer Ian F. Smith will deliver a presentation on Tuesday, April 8, 2025, at 8:45 a.m. ET. Stoke's lead investigational medicine, zorevunersen, is being developed as a potential first-in-class disease-modifying treatment for Dravet syndrome.

Investors and interested parties can access the live webcast and archived replay of the presentation through Stoke's website investor section at https://investor.stoketherapeutics.com/.

Stoke Therapeutics (NASDAQ: STOK) has reported its Q4 and full-year 2024 financial results, highlighting significant progress in its Dravet syndrome treatment program. The company's lead investigational medicine, zorevunersen, is advancing to Phase 3 EMPEROR study in Q2 2025.

Key financial highlights include:

• Cash position of $246.7 million as of December 31, 2024
• Full-year 2024 revenue of $36.6 million, up from $8.8 million in 2023
• Net loss of $89.0 million ($1.65 per share) in 2024, improved from $104.7 million in 2023

Notable developments include a new collaboration with Biogen, FDA Breakthrough Therapy Designation for zorevunersen, and positive clinical data presented at AES 2024. The company expects its current cash position, combined with the $165 million Biogen collaboration upfront payment, to fund operations until mid-2028.

Stoke Therapeutics (NASDAQ: STOK) announced a significant leadership transition as CEO Edward M. Kaye, M.D., will step down effective March 19, 2025. Ian F. Smith has been appointed Interim CEO, while Arthur Tzianabos, Ph.D., will serve as Interim Executive Chairman.

Dr. Kaye, who led the company for seven years, will continue as a board director and advisor. Under his leadership, Stoke achieved several milestones, including FDA Breakthrough Therapy Designation for zorevunersen, their lead investigational medicine for Dravet syndrome, positive data supporting potential disease modification, global Phase 3 alignment, and a partnership with Biogen.

Ian F. Smith brings over 20 years of biotechnology experience, previously serving as Executive VP, COO, and CFO at Vertex Pharmaceuticals. The Board has initiated a search for a permanent CEO as the company prepares for late-stage clinical development and commercialization.

Stoke Therapeutics (Nasdaq: STOK), a biotechnology company focused on RNA medicine for protein expression restoration, has announced its participation in two major investor conferences in March 2025:

• TD Cowen 45th Annual Healthcare Conference on Wednesday, March 5, 2025, at 9:50 a.m. ET
• Leerink Partners Global Healthcare Conference on Monday, March 10, 2025, at 10:40 a.m. ET

Live webcasts and archived replays of both presentations will be accessible through the Investors & News section of Stoke's website.